samedan logo
 
 
 
spacer
home > ebr > summer 2003 > the blossoming of biotechnology in wallonia
PUBLICATIONS
European Biopharmaceutical Review

The Blossoming of Biotechnology in Wallonia

R&D and entrepreneurship are closely linked. To be commercialised, R&D must be supported by entrepreneurial initiatives, and to make an initiative succeed, it needs to be based on competitive factors. R&D and biotechnology particularly have the potential to make a company highly competitive and bring strong added value.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Rudy Aernoudt, Deputy Head of Cabinet of the Walloon Ministry for Economy and Research

Rudy Aernoudt has studied Economics and Philosophy and holds a master's in European Economics. He was Special Adviser to the Belgian President of the Industry Council during the Belgian Presidency of the European Union.

As Deputy Head of Cabinet of the Walloon Ministry for Economy and Research, seconded by the European Commission, he deals with research, entrepreneurship and financing. He is also Professor in Corporate Finance at the business schools of Brussels, Ghent and Nancy. He has published books and articles on the topics of finance and politics.

spacer
Rudy Aernoudt
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avantor® Enters into Distribution Agreement to Supply Agilent Technologies’ Chemistries and Supplies Division products in the U.S. and Canada

Enabling analytical chemistry workflow laboratories full access to Agilent Technologies’ Chemistries & Supplies Division (CSD) portfolio - focusing on chromatography columns, sample preparation products, chemical standards, and spectroscopy supplies through Avantor’s leading digital and direct channels.
More info >>

White Papers

Convergence in the Pharmaceutical Market

PCI Pharma Services

Convergence is currently playing a large part in the growth of the pharmaceutical market. The need for convergence is due to many factors including the declining economy and high competition within the sector. There are many convergences within this sector to date; these include the convergence of food based products with medical and health products and the convergence of prescription drugs to over the counter (OTC) products. Although convergence is helping the pharmaceutical industry expand and develop, it also poses some challenges; these include the regulatory outlook and counterfeiting.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement